Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
Ruben Malmberg, Michiel Zietse, Daphne W. Dumoulin, Jeroen J. M. A. Hendrikx, Joachim G.J.V. Aerts, Astrid A.M. van der Veldt, Birgit C. P. Koch, Stefan Sleijfer, Roelof W. F. van Leeuwen
Topics & Concepts
PembrolizumabNivolumabDosingMedicineImmune checkpointOncologyImmunotherapyIntensive care medicineCancerInternal medicineCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchColorectal Cancer Treatments and Studies